Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PEPD | P12955 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15692147 | 1.00 | SMN1; SMN2 (0.33) | SMN1; SMN2TSHRPEPD | |
| SCHEMBL22992315 | 0.90 | SMN1; SMN2 (0.33) | SMN1; SMN2TSHRPEPD | |
| SCHEMBL20663571 | 0.88 | SMN1; SMN2 (0.32) | SMN1; SMN2TSHR | |
| SCHEMBL15038545 | 0.88 | SMN1; SMN2 (0.32) | SMN1; SMN2TSHR | |
| SCHEMBL19528383 | 0.88 | SMN1; SMN2 (0.32) | SMN1; SMN2TSHR | |
| SCHEMBL19884188 | 0.88 | SMN1; SMN2 (0.32) | SMN1; SMN2TSHR | |
| SCHEMBL19658166 | 0.88 | SMN1; SMN2 (0.33) | SMN1; SMN2TSHRPEPD | |
| SCHEMBL15038553 | 0.87 | DPP4 (0.34) | SMN1; SMN2TSHR | |
| SCHEMBL22992351 | 0.87 | DPP4 (0.34) | SMN1; SMN2TSHR | |
| SCHEMBL19529354 | 0.87 | DPP4 (0.34) | SMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3778606-A2 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2021-02-17 | — | — | EP | disclosed |
| EP-3699176-A2 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2020-08-26 | — | — | EP | disclosed |
| EP-3431477-A1 | CONDENSED IMIDAZOLYLIMIDAZOLES AS ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2019-01-23 | — | — | EP | disclosed |
| EP-2907816-B1 | Condensed imidazolylimidazoles as antiviral compounds | GILEAD PHARMASSET LLC (US) | 2018-06-13 | — | — | EP | disclosed |
| EP-3284741-A1 | ANTIVIRAL COMPOUNDS | Gilead Pharmasset LLC (US) | 2018-02-21 | — | — | EP | disclosed |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| US-9809600-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-11-07 | — | — | US | disclosed |
| EP-3239153-A1 | 9-(1H-IMIDAZOL-5-YL)-1,11-DIHYDROISOCHROMENO[4',3':6,7]NAPHTHO[1,2-D]IMIDAZOLE DERIVATIVES AND THEIR USE AS INHIBITORS OF HCV NS5A | Gilead Pharmasset LLC (US) | 2017-11-01 | — | — | EP | disclosed |
| EP-3239152-A1 | ANTIVIRAL COMPOUNDS | Gilead Sciences, Inc. (US) | 2017-11-01 | — | — | EP | disclosed |
| US-9682989-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2017-06-20 | — | — | US | disclosed |
| US-9051340-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-06-09 | — | — | US | disclosed |
| US-20150141326-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2015-05-21 | — | — | US | disclosed |
| US-8940718-B2 | Antiviral compounds | GILEAD PHARMASSET LLC (US) | 2015-01-27 | — | — | US | disclosed |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | GILEAD PHARMASSET LLC | 2014-10-23 | — | — | US | disclosed |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. | 2014-06-26 | — | — | US | disclosed |
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | Gelead Sciences, Inc. | 2014-01-16 | — | — | US | disclosed |
| US-8575135-B2 | Antiviral compounds | GILEAD SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140018313-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, ZC3HAV1 | SMN1; SMN2 1564/4885TSHR 4853/4885PEPD 389/4885 |
| US-20130177530-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885TSHR 4860/4885PEPD 1017/4885 |
| US-20170342085-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885TSHR 4860/4885PEPD 1017/4885 |
| US-20130156732-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885TSHR 4860/4885PEPD 1017/4885 |
| US-20130164260-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885TSHR 4860/4885PEPD 1017/4885 |
| US-20150141326-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885TSHR 4860/4885PEPD 1017/4885 |
| US-20140178336-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885TSHR 4860/4885PEPD 1017/4885 |
| US-20140316144-A1 | ANTIVIRAL COMPOUNDS | MAVS, EIF2AK2, SARS1 | SMN1; SMN2 816/4885TSHR 4860/4885PEPD 1017/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.